Provided by Tiger Fintech (Singapore) Pte. Ltd.

MediWound

16.66
+0.21001.28%
Pre-market: 16.30-0.3600-2.16%04:36 EDT
Volume:82.27K
Turnover:1.36M
Market Cap:180.06M
PE:-5.49
High:16.70
Open:16.38
Low:16.02
Close:16.45
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

MediWound: Q3 Earnings Snapshot

Associated Press Finance
·
26 Nov 2024

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

Benzinga
·
26 Nov 2024

Mediwound : Anticipates $20 Mln in Total Revenue for 2024

THOMSON REUTERS
·
26 Nov 2024

Mediwound Ltd FY2024 REV View $23.8 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
26 Nov 2024

Mediwound Q3 Net Income USD -10.3 Million

THOMSON REUTERS
·
26 Nov 2024

Mediwound Q3 Gross Profit USD 700 Thousand

THOMSON REUTERS
·
26 Nov 2024

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire
·
26 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
25 Nov 2024

Mediwound Ltd expected to post a loss of 44 cents a share - Earnings Preview

Reuters
·
22 Nov 2024

MediWound to Report Third Quarter 2024 Financial Results

GlobeNewswire
·
12 Nov 2024

MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year

Simply Wall St.
·
27 Oct 2024

Rosalind Advisors, Inc. Increases Stake in MediWound Ltd

GuruFocus.com
·
23 Oct 2024

MediWound Price Target Maintained With a $28.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Oct 2024

Mediwound’s EscharEx Poised for Growth: A Comprehensive Valuation and Buy Rating Amidst Clinical Studies

TIPRANKS
·
11 Oct 2024

MediWound to Begin Phase II Study of EscharEx Versus Collagenase in Venous Leg Ulcer Patients

MT Newswires Live
·
10 Oct 2024

BRIEF-MediWound Announces Phase II Head-To-Head Study Evaluating EscharEx vs Collagenase In Patients With Venous Leg Ulcers

Reuters
·
10 Oct 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."